myopharm.com/site/investors…

myopharm.com/site/pdf/8d6cb…

Today is World Diabetes Day! Our message is simple: Diabetes research changes lives and creates hope for the future. There is still a lot we don’t know about diabetes, and research is the only way we will drive change to prevent, treat and cure diabetes. diabetesaustralia.com.au/world-diabetes…

We were incredibly honoured that the American Diabetes Association(ADA) featured Myopharm Limited in the Thought Leadership Film Series, a part of ADA's 84th Scientific Sessions program in June 2024, starting on Friday.. youtu.be/YsCtbVLNXJU?si…

TriGlytza Mechanism Of Action (subtitled) youtu.be/Ye6l3dcU8HU?si… via YouTube

Watch Myoharm’s video on TriGlytza™as a pioneering treatment for type 2 diabetes, featured at American Diabetes Association’s Thought Leadership series: bit.ly/3KQWc15. ADA’s Scientific Sessions is the world’s largest diabetes meeting drawing over 11k industry professionals.

$PRO World's largest diabetes conference kicks off in Florida today tinyurl.com/2qad227s #PRO

A big thanks to Pharma Focus for this news coverage pharmainfocus.com.au/news_m.asp?new…

Myopharm are very pleased to announce the appointment of Dr Richard Mollard as Chief Scientific Officer and Chief Commercial Officer. myopharm.com/site/pdf/d9bcc…

National Diabetes Week Coverage Ticker speak to Myopharm CEO Karinza Phoenix youtu.be/pqENZh2HaM8

We're pleased to announce Tamara Miller as our new Head of Clinical Development. With 22+ years of clinical research experience and a background in biomedical science & project management, she's a valuable addition to our team. Join us in welcoming Tamara! #Myopharm #Biotech

Exciting New Appointments at Myopharm. We are pleased to announce the appointment of Dr George Tachas as Chief Scientific Officer and Advait Padhye as Research Associate. 🎉 Welcome to the team! #Type2diabetes#research#biotechnology#commercialisation

It’s here! The Int. Diabetes Fed.’s #DiabetesAtlas reveals staggering stats with $1T spent on diabetes in 2024. At Myopharm Limited, we’re committed to changing lives. Our drug candidate TriGlytza® and innovations OMNI-D® & OMNI-E® aim to be part of the answer. diabetesatlas.org

The wait is over! Myopharm's OMNI-D® TV commercial is live! OMNI-D® —clinically proven to reduce blood sugar spikes & support weight management. Watch: youtu.be/kTdTKHC_k0s Shop: myopharm.com/store #type2diabetes #InnovationInAction

Who is Myopharm? For those new to the Myopharm Limited story, we’ve put together a short video introducing who we are and what we do. Watch now and learn more! #Biopharmaceuticals #DiabetesInnovation

It’s Dietitians Week and it’s time we talk about their impact. Dietitians are critical contributors to the healthcare ecosystem. @Myopharm, we’re proud to support dietitians through OMNI-D and OMNI-e, products suitable for Type 2 Diabetics. To every dietitian, thank you.

We’re proud to partner with Diabetes Australia for a 3-year research collaboration, co-funding national PhD scholarships to tackle key diabetes challenges. Clinical trials of OMNI-D® to support this work. Launching National Diabetes Week 2025. #DiabetesPrevention #OMNID #PublicHealth

At @Myopharm, we support evidence-based care in metabolic & inflammatory diseases. Wiley’s infographic based on a recent study (lnkd.in/gp5V_Udqoffers) offers timely insights into real-world use of GLP-1RAs in obesity management. #GLP1 #TriGlytza #diabetesinnovation

New study links metformin to lower death rates in 100K+ women, including non-diabetics. @Myopharm’s TriGlytza can be used as adjunct therapy to metformin. Read ScienceAlert : sciencealert.com/common-diabete… #Metformin #TriGlytza #Type2Diabetes

Board Appointment: Dr Trevor Lockett joins @Myopharm Board as we advance OMNI-D® trials with Diabetes Australia. With 30+ years in biotech & molecular biology, Dr Lockett brings deep expertise from CSIRO, @RhythmBiosci & Juno Healthcare. #Biotech #Leadership #DiabetesCare #CSIRO